lorundrostat (MT-4129) / Mineralys Therap 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
lorundrostat (MT-4129) / Mineralys Therap
NCT06153693: Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

Completed
3
1083
Europe, Canada, US, RoW
Placebo, lorundrostat Dose 1, lorundrostat Dose 2
Mineralys Therapeutics Inc.
Hypertension
12/24
01/25
NCT05968430: Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects with Hypertension

Enrolling by invitation
3
1400
Europe, Canada, US, RoW
lorundrostat, Placebo
Mineralys Therapeutics Inc.
Hypertension
12/25
12/26
Target-HTN, NCT05001945: Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension

Completed
2
200
US
MLS-101 (Part I), Placebo (Part I), Placebo (Part II), MLS-101 (Part II)
Mineralys Therapeutics Inc.
Hypertension, Renal
09/22
10/22
NCT06150924: Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects with Hypertension and Chronic Kidney Disease (CKD) with Albuminuria

Active, not recruiting
2
60
US
Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD, Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD
Mineralys Therapeutics Inc.
Chronic Kidney Disease
05/25
05/25
NCT05769608: A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects with Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen

Completed
2
285
US
Placebo, lorundrostat Dose 1, lorundrostat Dose 2
Mineralys Therapeutics Inc.
Hypertension
01/25
01/25
NCT06326606: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 in Healthy Participants

Completed
1
24
RoW
Psilocybin, MLS101, Placebo
MycoMedica Life Sciences PBC
Healthy Volunteers
07/24
07/24

Download Options